Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Fineline Cube Mar 18, 2026
Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Fineline Cube Mar 18, 2026
Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Fineline Cube Mar 18, 2026
Company Deals

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

Fineline Cube Mar 18, 2026
Company Deals

PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug

Fineline Cube Mar 17, 2026
Policy / Regulatory

China Unveils NHSA Grassroots Healthcare Reform – 14‑Point Guidance Targets RMB Fund Flow Shift to Primary Care Institutions

Fineline Cube Mar 17, 2026
Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026
Company Drug

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

Fineline Cube Mar 18, 2026
Company

Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip

Fineline Cube Jul 21, 2023

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug

Fineline Cube Jul 21, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China

Fineline Cube Jul 21, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese...

Company Deals Digital

Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services

Fineline Cube Jul 20, 2023

China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with...

Drug

Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study

Fineline Cube Jul 20, 2023

Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...

Legal / IP Policy / Regulatory

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

Fineline Cube Jul 20, 2023

The United States has published an update to its merger and acquisition guidelines, seeking public...

Company Drug

Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy

Fineline Cube Jul 20, 2023

A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...

Company Drug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

Fineline Cube Jul 20, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...

Company Drug

Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine

Fineline Cube Jul 20, 2023

Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...

Company Drug

Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China

Fineline Cube Jul 20, 2023

The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...

Company Drug

HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer

Fineline Cube Jul 20, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...

Company Drug

Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826

Fineline Cube Jul 20, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...

Company Deals

Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology

Fineline Cube Jul 20, 2023

Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has...

Company Deals

Novomics Partners with TopGene to Expand Genomic Testing Services in China

Fineline Cube Jul 20, 2023

South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei...

Company

Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand

Fineline Cube Jul 20, 2023

China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended...

Company Deals

BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy

Fineline Cube Jul 20, 2023

China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment

Fineline Cube Jul 20, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...

Company Legal / IP

Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case

Fineline Cube Jul 20, 2023

Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...

Company Deals

Boyu Capital Acquires Hong Kong Medical Device Company Quasar for Over $600 Million

Fineline Cube Jul 19, 2023

Boyu Capital, according to a Bloomberg report, is set to acquire Quasar, a Hong Kong-based...

Company

Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth

Fineline Cube Jul 19, 2023

Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second...

Posts pagination

1 … 470 471 472 … 636

Recent updates

  • Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development
  • Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug
  • Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets
  • Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform
  • Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.